Although traditional renin–angiotensin system antagonists including angiotensin‐converting
enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of …

Despite significant advances in the last 30 years in reducing morbidity and mortality from
heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based …

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …

Angiotensin receptor-neprilysin inhibitors (ARNIs) are a new class of cardiovascular agents
characterized by their dual action on the major regulators of the cardiovascular system …

This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …

Heart failure affects≈ 5.7 million people in the United States alone. Angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists …

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the
mainstay of therapy for cardiovascular disease and heart failure (HF). The angiotensin …

Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has
been recommended in clinical practice guidelines to reduce morbidity and mortality in …

Background Sacubitril‐valsartan, an inhibitor of the angiotensin receptor neprilysin (ARNi),
has been purported to exhibit superiority over angiotensin converting enzyme (ACE) …